Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First in Human (FIH) single ascending dose Phase 1 study of ZKN-013 for the potential treatment of recessive dystrophic epidermolysis bullosa (RDEB)

Next Previous
X
Search
Trial Profile

A First in Human (FIH) single ascending dose Phase 1 study of ZKN-013 for the potential treatment of recessive dystrophic epidermolysis bullosa (RDEB)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZKN 013 (Primary)
  • Indications Epidermolysis bullosa dystrophica
  • Focus Adverse reactions; First in man
  • Sponsors Eloxx Pharmaceuticals

    • Most Recent Events

    • 11 Jul 2024 According to an Eloxx Pharmaceuticals media release, first two subjects have been dosed in this trial.
    • 11 Jul 2024 Status changed from planning to recruiting as per Eloxx Pharmaceuticals media release
    • 16 Apr 2024 According to an Eloxx Pharmaceuticals media release, initial results expected in 2nd half of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top